Skip to main content
Premium Trial:

Request an Annual Quote

Svar Life Science, Nimble Therapeutics Form Diagnostics Alliance

NEW YORK — Nimble Therapeutics and Svar Life Science said on Thursday that they have partnered on the development and commercialization of diagnostics for autoimmune diseases.

According to the companies, the alliance will initially focus on rheumatoid arthritis using biomarkers discovered using Nimble's human proteome immunoprofiling technology.

Under the terms of the deal, Nimble will receive an undisclosed upfront payment and stands to receive milestone payments and royalties on product sales. Additional terms were not disclosed.

"Partnering with Svar provides a strong commercial outlet for Nimble's discovery capabilities," Bradley Garcia, vice president of corporate development at Nimble, said in a statement.

Madison, Wisconsin-based Nimble, which was spun out of Roche a year ago, focuses on the discovery of novel peptide drugs using its parallel chemical synthesis platform. Malm, Sweden-based Svar — formerly Euro Diagnostica — develops assay technology for drug development and diagnostic applications.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.